Lesley Glenn

Lesley Glenn

Auto-generated profile, based on publicly available information

Lesley Glenn

Patient-Centered Dosing Initiative, New York, NY

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in JCO Oncology Practice
Verified
Journal Article
Closed access
ALAnne Loeser
Anne Loeser
JKJanice S. Kim
Janice S. Kim
JPJeffrey Peppercorn
Jeffrey Peppercorn
MBMark Burkard
Mark Burkard
ANAndrzej Niemierko
Andrzej Niemierko
ABAditya Bardia
Aditya Bardia
PURPOSE: Although patients with metastatic breast cancer (MBC) have been living longer with the advent of more effective treatments such as targeted therapy and immunotherapy, the disease remains incurable, and most patients will undergo therapy indefinitely. When beginning therapy, patients are typically prescribed dose often based upon the maximum tolerated dose identified in phase I clinical trials. However, patients' perspectives about tolerability and willingness to discuss individualized dosing of drugs upon initiation of a new regimen and throughout the course of treatment have not been comprehensively evaluated. METHODS: Patient advocates and medical oncologists from the Patient-Centered Dosing Initiative (PCDI) developed a survey to ascertain the prevalence and severity of MBC patients' treatment-related side effects, the level of patient-physician communication, mitigation strategies, perception about the relative efficacy of higher versus lower doses, and willingness to discuss alternative dosing. The PCDI distributed the anonymous confidential online survey in August 2020 to individuals with self-reported MBC. RESULTS: One thousand and two hundred twenty-one patients with MBC completed the survey. 86.1% (n = 1,051) reported experiencing at least one significant treatment-related side effect, and of these, 20.3% (n = 213) visited the emergency room/hospital and 43.2% (n = 454) missed at least one treatment. Nearly all patients with side effects (97.6%, n = 1,026) informed their doctor and 81.7% (n = 838) received assistance. Of the 556 patients given a dose reduction for side-effect mitigation, 82.6% (n = 459) reported relief. Notably, majority of patients (53.3%, n = 651) do not believe that higher dose is always more effective than lower dose, and 92.3% (n = 1,127) would be willing to discuss flexible dosing options with their physicians based upon personal characteristics to optimize quality of life. CONCLUSION: Given that the majority of patients with MBC experienced at least one substantial treatment-related side effect and most patients given a dose reduction reported improvement, innovative dosage-related strategies are warranted to sustain and improve patients' well-being. Patient-physician discussions in which the patient's unique attributes and circumstances are assessed upon initiation of new treatment and throughout the course of therapy may facilitate the identification of the most favorable dose for each patient, and the majority of patients would be receptive to this approach.

30 November 2023 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
MRMya Roberson
Mya Roberson
AHAnna Henricks
Anna Henricks
JWJoshua Woods
Joshua Woods
LGLesley Glenn
Lesley Glenn
JMJulia Maues
Julia Maues
SRSonya Reid
Sonya Reid
Purpose: While significant progress in metastatic breast cancer (MBC) treatment has prolonged survival and improved prognosis, there remain substantial gaps in providing patient-centered supportive care. The specific care delivery needs for metastatic cancer differ from that of early-stage cancer due to the incurable nature and lifelong duration of the condition. The objective of this study was to assess how patients living with MBC would re-imagine cancer care delivery. Methods: This qualitative study was conducted in partnership with patient-led organizations Guiding Researchers and Advocates to Scientific Partnerships (GRASP) and Project Life, a nonprofit, online wellness community founded by patients with MBC for patients living with MBC. Virtual semi-structured interviews (n = 36) were conducted with Project Life members purposively sampled from the groups’ overall membership. The interview guide contained items surrounding patients’ lived experiences of MBC, greatest unmet needs related to care, and perspectives on virtual wellness community involvement. Interviews were coded using two-stage deductive and inductive analysis. Results: Three major themes for re-imagining cancer care delivery were identified, including holistic care, information needs, and conceptual shifts. Within these several subthemes emerged with patients re-imagining referrals to non-oncological services, caregiver support, acceptance of integrative medicine, streamlined clinical trial enrollment, curated quality patient resources, MBC-specific terminology and approaches, long-term life and goal-of-care planning, and patient-centered voice throughout. Conclusion: People living with metastatic cancers have specific supportive care needs. These findings highlight patient-driven areas for re-imagination that are most salient for individuals with MBC.

7 October 2025 in JMIR Formative Research
Verified
Journal Article
Open access
CCClaire Conley
Claire Conley
EAElizabeth L Addington
Elizabeth L Addington
MVMikaela Velazquez-Sosa
Mikaela Velazquez-Sosa
BMBrenna Mossman
Brenna Mossman
LGLesley Glenn
Lesley Glenn
JMJudith T Moskowitz
Judith T Moskowitz
Background: Depression and anxiety are prevalent among patients with metastatic breast cancer (MBC), but there are few evidence-based psychological interventions specifically designed for this population. Objective: This study aimed to assess the feasibility, acceptability, and clinical impact of a multicomponent positive psychological intervention, enhanced with an ecological momentary intervention for symptom management, for patients with MBC. Methods: We recruited patients with MBC from a National Cancer Institute–designated comprehensive cancer center. Participants completed 5 weekly virtual individual sessions with a study counselor focused on positive emotion regulation skills. Participants also reported physical and psychological symptoms daily between sessions via SMS text messaging. Clinically elevated symptoms triggered a personalized coaching SMS text message tailored to the symptoms reported and the skills learned that week. Primary outcomes were intervention feasibility and acceptability. We also examined pre- to postintervention changes in depression, anxiety, positive affect, and positive emotion regulation skill use. Finally, a subset of participants completed qualitative exit interviews focusing on their experience in the study; interview data were analyzed using rapid qualitative analysis. Results: We approached 20 patients with MBC, established contact with 15 (75%), received consent from 10 (67%), and retained 9 (90%) patients through the end of the study. Participants were 55 (SD 14.4, range 35-75) years old on average and identified as non-Hispanic White (5/10, 50%), non-Hispanic Black (4/10, 40%), or Latina (1/10, 10%). Participants attended 92% (46/50) of intervention sessions (mean 50, SD 9, range 36‐71 min). On average, they completed 85% (SD 18%, range 46%-100%) of daily symptom assessments and received 23 (SD 5, range 13‐31) coaching messages. Participants reported high perceived intervention feasibility (mean 4.81/5, SD 0.44), acceptability (mean 4.78/5, SD 0.33), and appropriateness for patients with MBC (mean 4.83/5, SD 0.35), above our a priori cutoff of ≥4. All 9 participants (n=9, 100%) recommended the intervention for other patients with MBC. We observed pre- to postintervention decreases in depression (d=−0.32) and anxiety (d=−0.27) and increases in positive affect (d=0.30) and positive emotion regulation skill use (d=0.99). Rapid qualitative analysis results demonstrate participants’ positive experiences with the intervention, as well as suggestions for improvement. Conclusions: This pilot study supports the feasibility of enrolling and retaining racially and ethnically diverse patients with MBC to this trial, the acceptability of the positive psychological intervention enhanced with ecological momentary intervention, and preliminary intervention impacts on depression, anxiety, positive affect, and positive emotion regulation skill use. A large-scale randomized controlled trial is needed to assess intervention efficacy for outcomes of interest.

1 October 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MRMya Roberson
Mya Roberson
JWJoshua S Woods
Joshua S Woods
LGLesley Glenn
Lesley Glenn
JMJulia Maues
Julia Maues
DJDeltra James
Deltra James
SEShekinah Nefreteri Cluff Elmore
Shekinah Nefreteri Cluff Elmore
259 Background: Treatment advances for metastatic breast cancer (MBC) have markedly increased survival over the last several decades. Despite the clinical innovation that has occurred, there remains substantial fragmentation of care and lack of focused attention on MBC survivorship care. This study partnered with Project Life, an MBC-survivor led patient wellness community to assess MBC patient experiences with treatment experiences and social support services. Methods: We conducted, virtual, in-depth semi-structured qualitative interviews among people who were members of the Project Life Wellness community. The interview guide and study materials were developed in collaboration with Project Life leadership. A study flyer was distributed by Project Life to members that included a link to an eligibility survey. Participants were eligible if they self-identified as having MBC, were a member of the Project Life community, and could complete the interview in English. As part of the interview, we asked, “How would you re-imagine medical care for people with metastatic breast cancer?” We then systematically processed responses with phronetic iterative analysis, using the mixed-methods research software MAXQDA, to uncover contextually grounded, emergent themes through synthetic coding. Results: We interviewed 36 women with MBC who were members of the Project Life Wellness Community in Spring 2022. In terms of age, 8 (22%) participants were 30-45, 15 (42%) were 46-59, and 13 (36%) were 60+. Overall, 22% of participants identified as people of color (Black, Latina, or Asian). In response to how they would reimagine MBC care delivery, all participants touched upon dimensions of care coordination. Aspects of care coordination that participants specifically raised included 1) Organized referral processes for non-oncology care like mental health services, sexual health care, and palliative care; 2) The need for MBC-specific support services within the care setting; 3)Patient connection to psychosocial aspects of care including social work and patient navigation; 4) Streamlined processes for identifying and enrolling in clinical trials. Conclusions: In our investigation, when asked how they would reimagine MBC care delivery, participants overwhelmingly endorsed the need for more care coordination along several key domains. Responses highlighted the unique needs of care coordination specific to MBC patients. Future care innovations should center patient voices to ensure optimal impact.

3 March 2026 in JMIR Cancer
Verified
Journal Article
Open access
ETEmily P Taylor
Emily P Taylor
BMBrenna Mossman
Brenna Mossman
MVMikaela A Velazquez-Sosa
Mikaela A Velazquez-Sosa
ZRZaynab Rashid
Zaynab Rashid
NKNatalie Kloster
Natalie Kloster
CCClaire Conley
Claire Conley
Background: Patients with metastatic breast cancer (MBC) experience significant quality-of-life decrements, but there are few supportive care interventions specifically designed for this group that significantly improve quality of life. Ecological momentary assessment (EMA) and related ecological momentary interventions (EMIs) may be particularly beneficial for patients with MBC. However, no studies have previously examined the use of EMIs in the context of metastatic cancer. Objective: The purpose of this study was to qualitatively assess experiences with EMA and preferences for intervention content and mode among patients living with MBC, with an emphasis on EMIs. Methods: Women with MBC (n=29) were recruited from a longitudinal, observational study of quality of life using an EMA design. In-depth qualitative interviews assessed participants’ perspectives on the EMA design, including its feasibility, acceptability, and relevance to participants’ MBC experiences. Guided by participants’ EMA data, the interviews also examined the impact of self-monitoring and possible interventions when patients reported high symptom burden and/or low quality of life. Interviews were audio-recorded, transcribed verbatim, and analyzed using open coding, axial coding, and selective coding. The codebook was developed by reviewing a randomly selected subset of transcripts (n=5) and creating inductive, data-driven codes using the raw data, which were deductively organized into overarching themes. Results: Participants were mainly White (17/29, 59%), heterosexual (23/29, 79%), currently working (17/29, 59%), and held at least a bachelor’s degree (17/29, 59%). Participants had been living with MBC for a median of 2.5 years (range 0.2‐16.6 years). Most were diagnosed with hormone receptor-positive (23/29, 79%) and HER2-negative (21/29, 72%) breast cancer. Qualitative analysis identified 5 major themes. The participants reflected on their reasons for enrolling in the study, including interest in study activities and giving back to the MBC community (theme 1: participant engagement). Most participants found the EMA format easy to complete, and they provided recommendations for improving the design of future studies, including altering the timing and frequency of questionnaires (theme 2: feedback on study design). While less common, some participants discussed how engaging with the EMA protocol altered their experiences or behaviors (theme 3: impact of self-monitoring). Participants also discussed their reactions to seeing their EMA data, including their mixed thoughts on real-time data sharing (theme 4: responses to data). Finally, participants suggested programs and resources to improve their overall quality of life, reflecting on their interest in real-time interventions and peer-to-peer support (theme 5: recommendations for future interventions). Conclusions: Patients with MBC are willing to use EMA methodologies for data collection on quality of life and are open to EMIs with varying content and formats. Given variations in daily functioning between and within patients, a just-in-time adaptive intervention framework may be well suited for this population.